Managing Gallbladder Disease on Mounjaro (tirzepatide for T2D): The HealthRX.com Step-by-Step Protocol
At a glance
- Label rate / acute gallbladder disease 0.6% with Mounjaro vs 0% with placebo in adult placebo-controlled trials [1]
- Label statement for suspected stones / gallbladder diagnostic studies and clinical follow-up [1]
- Suspected pancreatitis / label says discontinue Mounjaro and initiate appropriate management [1]
- Meta-analysis / composite gallbladder or biliary disease RR 1.97, 95% CI 1.14 to 3.42, versus placebo or basal insulin [2]
- Mounjaro indication / type 2 diabetes in adults and children 10 years and older; not labeled for weight loss [1]
What does the Mounjaro label say?
Mounjaro is a once-weekly GIP and GLP-1 receptor agonist approved for type 2 diabetes and for reducing major cardiovascular events in adults with type 2 diabetes at high risk [1]. Its label lists acute gallbladder disease as a warning. In adult placebo-controlled trials, acute gallbladder disease (cholelithiasis, biliary colic and cholecystectomy) was reported by 0.6% of Mounjaro-treated patients and 0% of placebo-treated patients. The label's statement is specific: if cholelithiasis is suspected, gallbladder diagnostic studies and clinical follow-up are indicated [1].How common is gallbladder disease with tirzepatide?
A 2023 systematic review and meta-analysis pooled nine randomized trials with 9,871 participants and found the composite of gallbladder or biliary disease was significantly associated with tirzepatide compared with placebo or basal insulin, RR 1.97 (95% CI 1.14 to 3.42). It did not find a significant increase in cholelithiasis, cholecystitis or biliary disease individually [2].Which symptoms does the label describe?
For gallstones, the label gives no symptom list; it says only that gallbladder diagnostic studies and clinical follow-up are indicated if cholelithiasis is suspected [1]. For pancreatitis, it describes persistent or severe abdominal pain, sometimes radiating to the back, which may or may not come with nausea or vomiting [1]. Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia and abdominal pain are listed among the drug's common adverse reactions, reported in 5% or more of patients [1].Is gallbladder disease a reason to stop Mounjaro?
For suspected gallstones, the label's statement is gallbladder diagnostic studies and clinical follow-up; it does not say to discontinue Mounjaro [1]. For suspected acute pancreatitis, the label says to discontinue Mounjaro and initiate appropriate management [1].What about gallbladder surgery?
The label says pulmonary aspiration during general anesthesia or deep sedation has been reported in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures, and instructs patients to inform healthcare providers of any planned surgeries or procedures [1]. We found no published Mounjaro-specific hold or restart protocol for gallbladder surgery.Frequently asked questions
How common is gallbladder disease on Mounjaro?
In the Mounjaro label's adult placebo-controlled trials, acute gallbladder disease was reported by 0.6% of tirzepatide-treated patients and 0% of placebo-treated patients [1].
Does the label say to stop Mounjaro if I have gallstones?
No. For suspected cholelithiasis, the label's statement is gallbladder diagnostic studies and clinical follow-up [1]. It says to discontinue Mounjaro for suspected pancreatitis [1].
What pain pattern does the label link to pancreatitis?
The label describes persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting [1].
Does Mounjaro raise gallbladder risk in pooled trials?
A nine-trial meta-analysis found a higher composite of gallbladder or biliary disease with tirzepatide than with placebo or basal insulin (RR 1.97, 95% CI 1.14 to 3.42), without a significant increase in cholelithiasis, cholecystitis or biliary disease individually [2].
References
- U.S. National Library of Medicine, DailyMed. Mounjaro injection and KwikPen (tirzepatide) prescribing information. Mounjaro injection and KwikPen (tirzepatide) label
- Zeng Q, Xu J, Mu X, Shi Y, Fan H, Li S. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1214334. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis